Report: A survey conducted among the 27 high MDR-TB burden countries.
March – July 2015
Stop TB Partnership in collaboration with Medecins Sans Frontieres (MSF).
Accessed November 2017.
This book provides a perfect companion to BSAC’s FREE Massive Open Online Course on Antimicrobial Stewardship, which is available in English, Mandarin, Spanish, and Russian. Visit www.futurelearn.com/courses/antimicrobial-stewardship for details.
Please download the complete e-book form the websi...te (Large File 41 MB!)more
“Preferred product characteristics” (PPCs) are key tools to incentivize and guide the development of urgently needed health products. Some of the vector control interventions deployed in complex emergencies and in response to natural disasters – namely insecticide-treated nets (ITNs) and indoo...r residual spraying (IRS) – have already met identified public health needs in more stable settings; other tools such as insecticide-treated tarpaulins have been specifically designed for this use case. Given the diverse mix of existing and potential new interventions and the considerable gaps in the associated evidence base, this PPC aims to clearly articulate the unmet public health needs for tools designed to control malaria transmission in complex emergencies and in response to natural disasters.more
إن أهمية الفواكه والخضروات في النظم الغذائية الصحية والمغذية معروفة جيدًا ، وفي السنوات الأخيرة تم تشجيع المستهلكين على تناول المزيد من هذه المنتجات. بالنسبة للعدي...د من البلدان ، ولا سيما البلدان النامية ، أصبحت هذه المنتجات سلعة قيمة. وفي الوقت نفسه ، تتزايد مشكلات سلامة الأغذية المرتبطة باستهلاك الفواكه والخضروات الطازجة الملوثة بالكائنات الحية الدقيقةmore
A growing body of evidence demonstrates that hospital based programs dedicated to improving antibiotic use, commonly referred to as “Antibiotic Stewardship Programs (ASPs),” can both optimize the treatment of infections and reduce adverse events associated with antibiotic use. This document summ...arizes core elements of successful hospital Antibiotic Stewardship Programs. It complements existing guidelines on ASPs from different American organizations.more
The pre-clinical pipeline shows more innovation and diversity, with 252 agents being developed to treat WHO priority pathogens.
However, these products are in the very early stages of development and still need to be proven effective and safe. The optimistic scenario, the report indicates, is for... the first two to five products to become available in about 10 years.more